Cargando…

Cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids

PURPOSE: Unit-dose packaging systems are widely used and accepted practices in many hospitals in the US. When adopting a unit-dose, there are three different avenues in which pharmaceuticals can be obtained. Products can be purchased from a manufacturer-produced source, outsourced to repackaging by...

Descripción completa

Detalles Bibliográficos
Autor principal: Kelm, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307667/
https://www.ncbi.nlm.nih.gov/pubmed/35880109
http://dx.doi.org/10.1016/j.rcsop.2022.100157
_version_ 1784752814189182976
author Kelm, Matthew
author_facet Kelm, Matthew
author_sort Kelm, Matthew
collection PubMed
description PURPOSE: Unit-dose packaging systems are widely used and accepted practices in many hospitals in the US. When adopting a unit-dose, there are three different avenues in which pharmaceuticals can be obtained. Products can be purchased from a manufacturer-produced source, outsourced to repackaging by a 3rd-party repackaging service or repackaged in-house by investing in the technology and the resources to do so. Prior literature has suggested that manufacturer-based unit-dose purchasing was associated with a 1% cost savings over repackaged unit-dose. In this study, we hope to take a more extensive look at the cost and concerns associated specifically with unit dose liquids when purchased from a manufacturer, outsourced to a third party repackager, or repackaged from bulk bottles with in-house technology and resources. METHODS: A cost evaluation model, which factored in cost associated with used and expired product, was utilized to estimate and compare the cost of the three systems. RESULTS: Overall cost between the three systems was largely similar, although manufacturer-based repackaging was determined to be the most cost effective system. CONCLUSION: The results of this decision model analysis suggests that the cost associated with purchasing unit dose liquids from manufacturers, third party repackagers, and in-house repackaging are similar. Therefore, utilizing a specific system is unlikely to make a significant impact on the overall pharmaceutical budget for a large hospital or health system.
format Online
Article
Text
id pubmed-9307667
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93076672022-07-24 Cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids Kelm, Matthew Explor Res Clin Soc Pharm Article PURPOSE: Unit-dose packaging systems are widely used and accepted practices in many hospitals in the US. When adopting a unit-dose, there are three different avenues in which pharmaceuticals can be obtained. Products can be purchased from a manufacturer-produced source, outsourced to repackaging by a 3rd-party repackaging service or repackaged in-house by investing in the technology and the resources to do so. Prior literature has suggested that manufacturer-based unit-dose purchasing was associated with a 1% cost savings over repackaged unit-dose. In this study, we hope to take a more extensive look at the cost and concerns associated specifically with unit dose liquids when purchased from a manufacturer, outsourced to a third party repackager, or repackaged from bulk bottles with in-house technology and resources. METHODS: A cost evaluation model, which factored in cost associated with used and expired product, was utilized to estimate and compare the cost of the three systems. RESULTS: Overall cost between the three systems was largely similar, although manufacturer-based repackaging was determined to be the most cost effective system. CONCLUSION: The results of this decision model analysis suggests that the cost associated with purchasing unit dose liquids from manufacturers, third party repackagers, and in-house repackaging are similar. Therefore, utilizing a specific system is unlikely to make a significant impact on the overall pharmaceutical budget for a large hospital or health system. Elsevier 2022-07-13 /pmc/articles/PMC9307667/ /pubmed/35880109 http://dx.doi.org/10.1016/j.rcsop.2022.100157 Text en © 2022 The Author. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kelm, Matthew
Cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids
title Cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids
title_full Cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids
title_fullStr Cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids
title_full_unstemmed Cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids
title_short Cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids
title_sort cost evaluation model to compare in house repackaging, repackaging vendors, and sourcing unit dose medications from manufacturers for oral liquids
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307667/
https://www.ncbi.nlm.nih.gov/pubmed/35880109
http://dx.doi.org/10.1016/j.rcsop.2022.100157
work_keys_str_mv AT kelmmatthew costevaluationmodeltocompareinhouserepackagingrepackagingvendorsandsourcingunitdosemedicationsfrommanufacturersfororalliquids